The multiple mechanisms of amyloid deposition: The role of parkin

Prion

Volumn 3, Issue 1, 2009, Pages 5-11

  Mena, Maria A ^a   Rodríguez Navarro, José A ^a   De Yébenes, Justo García ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

amyloid; Alzheimer disease; Autophagy; Chaperones; Fronto temporal dementia; Parkin; Parkinson disease; Proteosome; PSP; Tau protein; Tauopathies; Transgenic mice

Indexed keywords

AMYLOID; PARKIN; PROTEASOME;

ALZHEIMER DISEASE; AMYLOIDOSIS; BEHAVIOR DISORDER; BRAIN LEVEL; DISEASE CLASSIFICATION; GENETIC ASSOCIATION; HUMAN; HUNTINGTON CHOREA; MOTOR DYSFUNCTION; NERVE DEGENERATION; NONHUMAN; NOTE; PARKINSONISM; PRION DISEASE; PROTEIN ASSEMBLY; PROTEIN FUNCTION; PROTEIN PROCESSING; PROTEIN SYNTHESIS; TAUOPATHY;

AMYLOID; AMYLOIDOSIS; ANALYSIS OF VARIANCE; ANIMALS; DISEASE MODELS, ANIMAL; HIPPOCAMPUS; HISTOCYTOCHEMISTRY; MICE; MICE, TRANSGENIC; NEURODEGENERATIVE DISEASES; PROTEASOME ENDOPEPTIDASE COMPLEX; UBIQUITIN-PROTEIN LIGASES;

MUS MUSCULUS;

EID: 66749117697     PISSN: 19336896     EISSN: 1933690X     Source Type: Journal    
DOI: 10.4161/pri.3.1.8122     Document Type: Note

References (88)

1. Virchow R. Ueber eine em Gehirn und Rückenmark des Menschen aufgefundene Substantz mit der chemischen Reaction der Cellulose. Arch Path Anat Klin Med 1854; 6:135-138
2. Cohen AS. Preliminary chemical analysis of partially purified amyloid fibrils. Am J Pharm Sci Support Public Health 1966; 15:66-83.
3. Glenner GG, Eanes ED, Bladen HA, Linke RP, Termine JD. Beta-pleated sheet fibrils. A comparison of native amyloid with synthetic protein fibrils. J Histochem Cytochem 1974; 22:1141-1158
4. Schwartz P. Amyloidosis as a manifestation and origin of presenile and senile degeneration. Fortschr Med 1976; 94:890-896
5. Gruys E. Protein folding pathology in domestic animals. J Zhejiang Univ Sci 2004; 5:1226-1238 (Pubitemid 40017136)
6. Meyer-Luehmann M, Spires-Jones TL, Prada C, Garcia-Alloza M, de Calignon A, Rozkalne A, et al. Rapid appearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimer's disease. Nature 2008; 451:720-724
7. Bolmont T, Haiss F, Eicke D, Radde R, Mathis CA, Klunk WE, et al. Dynamics of the microglial/amyloid interaction indicate a role in plaque maintenance. J Neurosci 2008; 28:4283-4292
8. Jarrett JT, Lansbury PT Jr. Seeding "one-dimensional crystallization" of amyloid: a pathogenic mechanism in Alzheimer's disease and scrapie? Cell 1993; 73:1055-1058
9. Eckenhoff RG, Johansson JS, Wei H, Carnini A, Kang B, Wei W, et al. Inhaled anesthetic enhancement of amyloid-beta oligomerization and cytotoxicity. Anesthesiology 2004; 101:703-709 (Pubitemid 39121650)
10. Troncoso JC, Zonderman AB, Resnick SM, Crain B, Pletnikova O, O'Brien RJ. Effect of infarcts on dementia in the Baltimore longitudinal study of aging. Ann Neurol 2008; 64:168-176
11. Buchman AS, Schneider JA, Leurgans S, Bennett DA. Physical frailty in older persons is associated with Alzheimer disease pathology. Neurology 2008; 71:499-504.
12. Palotas M, Palotas A, Bjelik A, Pakaski M, Hugyecz M, Janka Z, Kalman J. Effect of general anesthetics on amyloid precursor protein and mRNA levels in the rat brain. Neurochem Res 2005; 30:1021-1026 (Pubitemid 41570037)
13. Kuehn BM. Anesthesia-Alzheimer disease link probed. Jama 2007; 297:1760. (Pubitemid 46658664)
14. Nomenclature of amyloid and amyloidosis. WHO-IUIS Nomenclature Sub-Committee. Bull World Health Organ 1993; 71:105-112
15. Westermark P, Benson MD, Buxbaum JN, Cohen AS, Frangione B, Ikeda S, et al. A primer of amyloid nomenclature. Amyloid 2007; 14:179-183 (Pubitemid 47262691)
16. Lossos A, Soffer D, Steiner-Birmanns B, Hassin-Baer S, Sadeh M, Sagi M, et al. Extended phenotype in the transthyretin Tyr77 familial amyloid polyneuropathy. Eur Neurol 2005; 53:55-59 (Pubitemid 40868701)
17. Giannakopoulos P, Herrmann FR, Bussiere T, Bouras C, Kovari E, Perl DP, et al. Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer's disease. Neurology 2003; 60:1495-1500 (Pubitemid 36559525)
18. Matsuoka Y, Jouroukhin Y, Gray AJ, Ma L, Hirata-Fukae C, Li HF, et al. A neuronal microtubule-interacting agent, NAPVSIPQ, reduces tau pathology and enhances cognitive function in a mouse model of Alzheimer's disease. J Pharmacol Exp Ther 2008; 325:146-153
19. Gotz J, Chen F, van Dorpe J, Nitsch RM. Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils. Science 2001; 293:1491-1495 (Pubitemid 32807681)
20. Lewis J, Dickson DW, Lin WL, Chisholm L, Corral A, Jones G, et al. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 2001; 293:1487-1491 (Pubitemid 32801551)
21. Oddo S, Billings L, Kesslak JP, Cribbs DH, LaFerla FM. Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron 2004; 43:321-332 (Pubitemid 39061125)
22. Oddo S, Caccamo A, Cheng D, Jouleh B, Torp R, LaFerla FM. Genetically augmenting tau levels does not modulate the onset or progression of Abeta pathology in transgenic mice. J Neurochem 2007; 102:1053-1063 (Pubitemid 47174220)
23. Guo JP, Arai T, Miklossy J, McGeer PL. Abeta and tau form soluble complexes that may promote self aggregation of both into the insoluble forms observed in Alzheimer's disease. Proc Natl Acad Sci USA 2006; 103:1953-1958 (Pubitemid 43228799)
24. Roberson ED, Scearce-Levie K, Palop JJ, Yan F, Cheng IH, Wu T, et al. Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science 2007; 316:750-754 (Pubitemid 46717684)
25. Nalivaeva NN, Fisk LR, Belyaev ND, Turner AJ. Amyloid-degrading enzymes as therapeutic targets in Alzheimer's disease. Curr Alzheimer Res 2008; 5:212-224
26. Ito S, Ohtsuki S, Kamiie J, Nezu Y, Terasaki T. Cerebral clearance of human amyloid-beta peptide (1-40) across the blood-brain barrier is reduced by self-aggregation and formation of low-density lipoprotein receptor-related protein-1 ligand complexes. J Neurochem 2007; 103:2482-2490
27. Rubio I, Caramelo C, Gil A, Lopez MD, de Yebenes JG. Plasma amyloid-beta, Abeta1-42, load is reduced by haemodialysis. J Alzheimers Dis 2006; 10:439-443
28. Ciechanover A, Brundin P. The ubiquitin proteasome system in neurodegenerative diseases: sometimes the chicken, sometimes the egg. Neuron 2003; 40:427-446 (Pubitemid 37244106)
29. Bulteau AL, Petropoulos I, Friguet B. Age-related alterations of proteasome structure and function in aging epidermis. Exp Gerontol 2000; 35:767-777
30. Keller JN, Hanni KB, Markesbery WR. Possible involvement of proteasome inhibition in aging: implications for oxidative stress. Mech Ageing Dev 2000; 113:61-70. (Pubitemid 30050671)
31. van Leeuwen FW, de Kleijn DP, van den Hurk HH, Neubauer A, Sonnemans MA, Sluijs JA, et al. Frameshift mutants of beta amyloid precursor protein and ubiquitin-B in Alzheimer's and Down patients. Science 1998; 279:242-247 (Pubitemid 28103884)
32. David DC, Layfield R, Serpell L, Narain Y, Goedert M, Spillantini MG. Proteasomal degradation of tau protein. J Neurochem 2002; 83:176-185
33. Keck S, Nitsch R, Grune T, Ullrich O. Proteasome inhibition by paired helical filament-tau in brains of patients with Alzheimer's disease. J Neurochem 2003; 85:115-122 (Pubitemid 36389701)
34. Skovronsky DM, Pijak DS, Doms RW, Lee VM. A distinct ER/IC gamma-secretase competes with the proteasome for cleavage of APP. Biochemistry 2000; 39:810-817 (Pubitemid 30065051)
35. Nunan J, Shearman MS, Checler F, Cappai R, Evin G, Beyreuther K, et al. The C-terminal fragment of the Alzheimer's disease amyloid protein precursor is degraded by a proteasome-dependent mechanism distinct from gamma-secretase. Eur J Biochem 2001; 268:5329-5336 (Pubitemid 32948359)
36. Nunan J, Williamson NA, Hill AF, Sernee MF, Masters CL, Small DH. Proteasome-mediated degradation of the C-terminus of the Alzheimer's disease beta-amyloid protein precursor: effect of C-terminal truncation on production of beta-amyloid protein. J Neurosci Res 2003; 74:378-385 (Pubitemid 37362814)
37. Qing H, Zhou W, Christensen MA, Sun X, Tong Y, Song W. Degradation of BACE by the ubiquitin-proteasome pathway. Faseb J 2004; 18:1571-1573 (Pubitemid 39561636)
38. Bergman A, Hansson EM, Pursglove SE, Farmery MR, Lannfelt L, Lendahl U, et al. Pen-2 is sequestered in the endoplasmic reticulum and subjected to ubiquitylation and proteasome-mediated degradation in the absence of presenilin. J Biol Chem 2004; 279:16744-16753 (Pubitemid 38509377)
39. Crystal AS, Morais VA, Fortna RR, Carlin D, Pierson TC, Wilson CA, et al. Presenilin modulates Pen-2 levels posttranslationally by protecting it from proteasomal degradation. Biochemistry 2004; 43:3555-3563 (Pubitemid 38391710)
40. Kim TW, Pettingell WH, Hallmark OG, Moir RD, Wasco W, Tanzi RE. Endoproteolytic cleavage and proteasomal degradation of presenilin 2 in transfected cells. J Biol Chem 1997; 272:11006-11010 (Pubitemid 27184087)
41. Fraser PE, Levesque G, Yu G, Mills LR, Thirlwell J, Frantseva M, et al. Presenilin 1 is actively degraded by the 26S proteasome. Neurobiol Aging 1998; 19:19-21. (Pubitemid 28178933)
42. He G, Qing H, Cai F, Kwok C, Xu H, Yu G, et al. Ubiquitin-proteasome pathway mediates degradation of APH-1. J Neurochem 2006; 99:1403-1412 (Pubitemid 44730094)
43. He G, Qing H, Tong Y, Cai F, Ishiura S, Song W. Degradation of nicastrin involves both proteasome and lysosome. J Neurochem 2007; 101:982-992 (Pubitemid 46683872)
44. Abbas N, Lucking CB, Ricard S, Durr A, Bonifati V, De Michele G, et al. A wide variety of mutations in the parkin gene are responsible for autosomal recessive parkinsonism in Europe. French Parkinson's Disease Genetics Study Group and the European Consortium on Genetic Susceptibility in Parkinson's Disease. Hum Mol Genet 1999; 8:567-574 (Pubitemid 29139969)
45. Kitada T, Asakawa S, Hattori N, Matsumine H, Yamamura Y, Minoshima S, et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 1998; 392:605-608 (Pubitemid 28207717)
46. Klein C, Lohmann-Hedrich K. Impact of recent genetic findings in Parkinson's disease. Curr Opin Neurol 2007; 20:453-464 (Pubitemid 47051994)
47. Lucking CB, Durr A, Bonifati V, Vaughan J, De Michele G, Gasser T, et al. Association between early-onset Parkinson's disease and mutations in the parkin gene. N Engl J Med 2000; 342:1560-1567 (Pubitemid 30340501)
48. Shimura H, Hattori N, Kubo S, Mizuno Y, Asakawa S, Minoshima S, et al. Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat Genet 2000; 25:302-305 (Pubitemid 30437317)
49. Morales B, Martinez A, Gonzalo I, Vidal L, Ros R, Gomez-Tortosa E, et al. Steele-Richardson-Olszewski syndrome in a patient with a single C212Y mutation in the parkin protein. Mov Disord 2002; 17:1374-1380 (Pubitemid 36041361)
50. Ros R, Ampuero I, Garcia de Yebenes J. Parkin polymorphisms in progressive supranuclear palsy. J Neurol Sci 2007.
51. Rodriguez-Navarro JA, Gomez A, Rodal I, Perucho J, Martinez A, Furio V, et al. Parkin deletion causes cerebral and systemic amyloidosis in human mutated tau overexpressing mice. Hum Mol Genet 2008; 17:3128-3143
52. Menendez J, Rodriguez-Navarro JA, Solano RM, Casarejos MJ, Rodal I, Guerrero R, et al. Suppression of Parkin enhances nigrostriatal and motor neuron lesion in mice overexpressing human-mutated tau protein. Hum Mol Genet 2006; 15:2045-2058 (Pubitemid 43923395)
53. Klein RL, Dayton RD, Henderson KM, Petrucelli L. Parkin is protective for substantia nigra dopamine neurons in a tau gene transfer neurodegeneration model. Neurosci Lett 2006; 401:130-135
54. Rodriguez-Navarro JA, Casarejos MJ, Menendez J, Solano RM, Rodal I, Gomez A, et al. Mortality, oxidative stress and tau accumulation during ageing in parkin null mice. J Neurochem 2007; 103:98-114. (Pubitemid 47404223)
55. Kitada T, Asakawa S, Minoshima S, Mizuno Y, Shimizu N. Molecular cloning, gene expression and identification of a splicing variant of the mouse parkin gene. Mamm Genome 2000; 11:417-421 (Pubitemid 30407403)
56. Whitworth AJ, Theodore DA, Greene JC, Benes H, Wes PD, Pallanck LJ. Increased glutathione S-transferase activity rescues dopaminergic neuron loss in a Drosophila model of Parkinson's disease. Proc Natl Acad Sci USA 2005; 102:8024-8029 (Pubitemid 40781056)
57. Paciello O, Wojcik S, Engel WK, McFerrin J, Askanas V. Parkin and its association with alpha-synuclein and AbetaPP in inclusion-body myositis and AbetaPP-overexpressing cultured human muscle fibers. Acta Myol 2006; 25:13-22. (Pubitemid 44258676)
58. Rosen KM, Veereshwarayya V, Moussa CE, Fu Q, Goldberg MS, Schlossmacher MG, et al. Parkin protects against mitochondrial toxins and beta-amyloid accumulation in skeletal muscle cells. J Biol Chem 2006; 281:12809-12816 (Pubitemid 43855373)
59. Kenner L, el-Shabrawi Y, Hutter H, Forstner M, Zatloukal K, Hoefler G, et al. Expression of three- and four-repeat tau isoforms in mouse liver. Hepatology 1994; 20:1086-1089
60. Kenner L, Zatloukal K, Stumptner C, Eferl R, Denk H. Altered microtubule-associated tau messenger RNA isoform expression in livers of griseofulvin- and 3,5-diethoxycarbonyl-1, 4-dihydrocollidine-treated mice. Hepatology 1999; 29:793-800. (Pubitemid 29109593)
61. Hatakeyama S, Matsumoto M, Kamura T, Murayama M, Chui DH, Planel E, et al. U-box protein carboxyl terminus of Hsc70-interacting protein (CHIP) mediates polyubiquitylation preferentially on four-repeat Tau and is involved in neurodegeneration of tauopathy. J Neurochem 2004; 91:299-307. (Pubitemid 39363429)
62. Petrucelli L, Dickson D, Kehoe K, Taylor J, Snyder H, Grover A, et al. CHIP and Hsp70 regulate tau ubiquitination, degradation and aggregation. Hum Mol Genet 2004; 13:703-714 (Pubitemid 38455958)
63. Shimura H, Schwartz D, Gygi SP, Kosik KS. CHIP-Hsc70 complex ubiquitinates phosphorylated tau and enhances cell survival. J Biol Chem 2004; 279:4869-4876 (Pubitemid 38199082)
64. Dickey CA, Kamal A, Lundgren K, Klosak N, Bailey RM, Dunmore J, et al. The high-affinity HSP90-CHIP complex recognizes and selectively degrades phosphorylated tau client proteins. J Clin Invest 2007; 117:648-658 (Pubitemid 46348523)
65. Dickey CA, Yue M, Lin WL, Dickson DW, Dunmore JH, Lee WC, et al. Deletion of the ubiquitin ligase CHIP leads to the accumulation, but not the aggregation, of both endogenous phospho- and caspase-3-cleaved tau species. J Neurosci 2006; 26:6985-6996 (Pubitemid 44309866)
66. Sahara N, Murayama M, Mizoroki T, Urushitani M, Imai Y, Takahashi R, et al. In vivo evidence of CHIP upregulation attenuating tau aggregation. J Neurochem 2005; 94:1254-1263
67. Babu JR, Geetha T, Wooten MW. Sequestosome 1/p62 shuttles polyubiquitinated tau for proteasomal degradation. J Neurochem 2005; 94:192-203. (Pubitemid 40911405)
68. Kuusisto E, Salminen A, Alafuzoff I. Ubiquitin-binding protein p62 is present in neuronal and glial inclusions in human tauopathies and synucleinopathies. Neuroreport 2001; 12:2085-2090 (Pubitemid 32646250)
69. Kuusisto E, Salminen A, Alafuzoff I. Early accumulation of p62 in neurofibrillary tangles in Alzheimer's disease: possible role in tangle formation. Neuropathol Appl Neurobiol 2002; 28:228-237 (Pubitemid 34639445)
70. Magrane J, Smith RC, Walsh K, Querfurth HW. Heat shock protein 70 participates in the neuroprotective response to intracellularly expressed beta-amyloid in neurons. J Neurosci 2004; 24:1700-1706 (Pubitemid 38240967)
71. Kumar P, Ambasta RK, Veereshwarayya V, Rosen KM, Kosik KS, Band H, et al. CHIP and HSPs interact with {beta}-APP in a proteasome-dependent manner and influence A{beta} metabolism. Hum Mol Genet 2007; 16: 848-864. (Pubitemid 47061630)
72. Oddo S, Caccamo A, Tseng B, Cheng D, Vasilevko V, Cribbs DH, LaFerla FM. Blocking Abeta42 accumulation delays the onset and progression of tau pathology via the C terminus of heat shock protein70-interacting protein: a mechanistic link between Abeta and tau pathology. J Neurosci 2008; 28:12163-12175
73. Imai Y, Soda M, Hatakeyama S, Akagi T, Hashikawa T, Nakayama KI, Takahashi R. CHIP is associated with Parkin, a gene responsible for familial Parkinson's disease, and enhances its ubiquitin ligase activity. Mol Cell 2002; 10:55-67. (Pubitemid 34876562)
74. Ramesh Babu J, Lamar Seibenhener M, Peng J, Strom AL, Kemppainen R, Cox N, et al. Genetic inactivation of p62 leads to accumulation of hyperphosphorylated tau and neurodegeneration. J Neurochem 2008; 106:107-120
75. Bjorkoy G, Lamark T, Brech A, Outzen H, Perander M, Overvatn A, et al. p62/SQSTM1 forms protein aggregates degraded by autophagy and has a protective effect on huntingtin-induced cell death. J Cell Biol 2005; 171:603-614 (Pubitemid 41668720)
76. Bjorkoy G, Lamark T, Johansen T. p62/SQSTM1: a missing link between protein aggregates and the autophagy machinery. Autophagy 2006; 2:138-139
77. Olzmann JA, Chin LS. Parkin-mediated K63-linked polyubiquitination: a signal for targeting misfolded proteins to the aggresome-autophagy pathway. Autophagy 2008; 4:85-87
78. Komatsu M, Waguri S, Chiba T, Murata S, Iwata J, Tanida I, et al. Loss of autophagy in the central nervous system causes neurodegeneration in mice. Nature 2006; 441:880-884 (Pubitemid 43910422)
79. Lim F, Hernandez F, Lucas JJ, Gomez-Ramos P, Moran MA, Avila J. FTDP-17 mutations in tau transgenic mice provoke lysosomal abnormalities and Tau filaments in forebrain. Mol Cell Neurosci 2001; 18:702-714 (Pubitemid 34060150)
80. Narendra D, Tanaka A, Suen DF, Youle RJ. Parkin is recruited selectively to impaired mitochondria and promotes their autophagy. J Cell Biol 2008; 183:795-803.
81. Casarejos MJ, Menendez J, Solano RM, Rodriguez-Navarro JA, Garcia de Yebenes J, Mena MA. Susceptibility to rotenone is increased in neurons from parkin null mice and is reduced by minocycline. J Neurochem 2006; 97:934-946
82. Casarejos MJ, Solano RM, Menendez J, Rodriguez-Navarro JA, Correa C, Garcia de Yebenes J, et al. Differential effects of l-DOPA on monoamine metabolism, cell survival and glutathione production in midbrain neuronal-enriched cultures from parkin knockout and wild-type mice. J Neurochem 2005; 94:1005-1014 (Pubitemid 41170588)
83. Frank-Cannon TC, Tran T, Ruhn KA, Martinez TN, Hong J, Marvin M, et al. Parkin deficiency increases vulnerability to inflammation-related nigral degeneration. J Neurosci 2008; 28:10825-10834
84. Solano RM, Casarejos MJ, Menendez-Cuervo J, Rodriguez-Navarro JA, Garcia de Yebenes J, Mena MA. Glial dysfunction in parkin null mice: effects of aging. J Neurosci 2008; 28:598-611.
85. Rojo LE, Fernandez JA, Maccioni AA, Jimenez JM, Maccioni RB. Neuroinflammation: implications for the pathogenesis and molecular diagnosis of Alzheimer's disease. Arch Med Res 2008; 39:1-16. (Pubitemid 350192021)
86. Benbunan BR, Korczyn AD, Giladi N. Parkin mutation associated parkinsonism and cognitive decline. Comparison to early onset Parkinson's disease. J Neural Trans 2004; 111:47-57. (Pubitemid 38177817)
87. Mori H, Kondo T, Yokochi M, Matsumine H, Nakagawa-Hattori Y, Miyake T, et al. Pathologic and biochemical studies of juvenile parkinsonism linked to chromosome 6q. Neurology 1998; 51:890-892 (Pubitemid 28449284)
88. Van de Warremburg BP, Lammens M, Lükings CB, Denèfle P, Wesseling P, Booij J, et al. Clinical and pathologic abnormalities in a family with parkinsonism and parkin gene mutations. Neurology 2001; 56:555-557 (Pubitemid 32172889)